Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE001 (USA) (Dr. Reyes)
· consented 2023-01-03
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-03 (study day 46); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 55); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-26 (study day 100); relationship: N; serious criteria: life-threatening
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-12 (study day 116); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-31 (study day 135); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-19 (study day 246); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.